CLSN - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Bobby, and I will be your operator today. At this time, I would like to welcome you to the Celsion Corporation 's Third Quarter 2021 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise.

Following the speaker's prepared remarks, there will be a question-and-answer session. [Operator the this Golodetz. call may like I you turn to over Instructions], Instructions] time, At would [Operator to Kim go ahead. Please

Kim Golodetz

with business update Thank is Third morning good call. XXXX HLA. Golodetz Quarter and you. Celsion's Welcome results everyone. financial to And Kim This

will been remarks practice operator, Celsion's a by has as noted followed As the question-and-answer by and prepared be session.

any can COVID-XX such be events. call, and to made this as Celsion expectations at identified XXth, including results about future conference call the financial content the undertakes -- Generally, call actual duration During and results estimate other no be today's statements said, These periodic the Tardugno, regarding by Michael? anticipates, Celsion those during uncertainties, for is similar XXXX. pandemic. means obligation the the this today's such Michael and that like as and number of as and discussion. in COVID-XX statements forth November may on law. on filings to or differ expects, the and and statements date Celsion's materially Securities subject turn Chairman, the the In update an information revise could based This terminologies Commission. broadcast, only CEO that I'd call, required believes, or with results Exchange over With about comments is from are particular, there of live outlook of making to impact change forward-looking also to I President. Company's by uncertainty except a operations, management caution best the on the impact of contemplated of of time the current is be accurate forward-looking will are statements guaranteed risks can and statements. there and set forward-looking expressions. projections expectations significant based is No

Michael Tardugno

morning, you, everyone. Thank Good Kim.

Jeffrey Nicholas regarding our in who Anwer, will Q&A vaccine questions available GEN-X are answer work Dr. Celsion's financial Officer Church, today third our Officer, Chief our Chief and be and Khursheed Officer, will Borys, Medical review Joining your to me session moment, results our during the quarter with Chief a our Science Financial just Dr. initiative.

quarter, to plasid progress research third continued the make proprietary our programs, leading During technology. we with our -based utilizing

reach our sheet access hypothesis need Celsion randomized the note promising As at for study very milestones to for were preclinical next the releases, our vaccine. balance our to agent that you for early of complete and note the investigational proof-of-concept report outcomes during for data Vaccines in we through supporting oral -oncology improve without expect last for year PLACCINE Congress GEN-X presented and press October, clinical final product, recruiting to of readout key patients our the of may our GEN-X potential immediate advanced cancer. capital. Also PLACCINE -based strong reported plasmid in our additional with results vaccine immune Phase from immuno are non ability A dilutive X ovarian - were lead its potential. observations sources technology our DNA immunization sessions system, with the formulated By of International this along capital while

a cancer. historical to ovarian response, us data synthetic published studies appears compared construction well-known its It Access plasmid understanding focus with the well-respected I has and while our And believe TheraPlas, favorable I'll much and periods by provides and Phase our II DNA from recent demonstrated Phase from advisors delivery diagnosed encoded clinical we see or newly Now, incorporates drug our study. are briefly programs GEN-X candidate these surgical study, extended is over cell now. on advanced the successful X phase to translational highly leading time, of firmly the lead basis program. X of ovarian is ability platform. synthetic in platforms. product this responses. is when end transfection as when and is DNA platform, clear our consistent as Medidata. survival of vector IL-XX. study months GEN-X cancer patients Published TheraPlas for highly to the first in on pharmacology IL-XX, cytokine, and our link catalysts data. that these data medical the to the observed improvements Progression-free the the -- into environment data them tumor unequivocally, review a plasmid in technology repeatedly data macro to in powerful website. platform. ability environment, compared for a There's appear successfully its publication results, the deliver has to our is in update and underlies X for non-viral the our discussing be heard in release support the shifting suppressive dose the anti-cancer continued -- These pathological as our coming pro-immune that of these plasmid a shown, can micro research supportive dependent on modify small important our provide in-depth an provided press and controller our on tumor immuno development trends biological trials to we, of a CRO management Celsion's of

open-label research the XX clinical is % an premier centers. in to potential or and treatment Wash cancer X that's in of trial This University study observed X.XX, terms in designed centers of PFS, GEN-X for San control to UC improve ovarian PFS among being U, Diego, in treatment conducted in study diagnosed one improvement Cooper, General, comparing approximate Wisconsin, Langone, University The XX including Alabama, median OVATION arm MD arm. hazard is evaluating risk GEN-X layman's Madison, advanced U.S. the patients. progression when interval our with the and for XX means time now cancer and an NYU progression-free % progression Phase II randomized Mass the newly an survival Canada, Anderson ratio other naive, confidence are with We which of

as as accrued at patients and As population. XXX target release, as the in is the noted minimum enrollment few will we approaching morning's many XXX, % this now study and XX press as have

will to the early the XX readout the enrollment half complete depending upon of in when in the patients the or comes somewhere in on occurs, readout -- number This of XX whichever end, sorry, in first first study, the time final I'm or quarter XXXX. occurring data study PFS first first. expect half, occur We PFS months put median the with

single preclinical mRNA-based baseline vaccines, evaluated PLACCINE vaccine plasmid is encoded with synthetic comparator. design in next-generation is delivered its Now is initiative proprietary DNA onto current the delivery which multiple in hypothesis proof-of-concept PLACCINE platform, using a with non-viral for a DNA polymer. vector, our platform, of our PLACCINE. antigens is second the iteration, viral a being

to vaccines construct Our working the to of of plasmid potential a a be hypothesis superior mRNA this has ways. is number in that DNA

For is The response multiple antibodies higher variance of expected superior. example, antigens T-cell virus and dependent to response quality the strains will be G that vaccine the will improved immune comprised plasmid titers IGG of of against antigens neutralizing affinity multiple immunity. or possibility, be a escape immunoglobulin reducing the evolving through

DNA mRNA. workable a temperatures. more due we product response immune from many of to of more and on our expression experience with based the commercially-appealing, stable of And expect duration longer a years expect versus longer antigen duration We GEN-X,

response our We of In or vivo the CoV to exposure we BALB/c and -clinical predicts of - spike of pre to ability -X our results of noted the of are studies production antigen cells COVID SARS our When a against - with viral the mice fourth-generation specific assay. to T-cell construct, production shows the presented to so stability September, PLACCINE side X, Congress antibodies faster far. deal neutralizing work showing Anwer vaccine - to protect the of variance, SARS in progress immunizing announced The pleased infection Celsius SARS-CoV-X. we prevented and facilitate antibodies and elicitation from vector of of degrees a to with X of effects Dr. against suggesting antigens SARS-CoV-X were establish proof-of-concept response in spike and in demonstrate vaccines T-cells cultured more antibodies CoV -XX. to we -- vaccines. early spectrum there's at findings to Chief Science compared October. to temperatures a the fully manufacturing's These infected noted potential our cytotoxic Khursheed also and potential by Vaccines from great expect International ourselves with kit cheaper and He which storage improved above, eradicate broad infected the that resistance at and do protection our Officer, mRNA

why are longer-term, big So where program are of to by going deep devoting on vaccines now? to committed Clearly, She note resources the of and commercial we're being market, several the pharma. SARS-CoV-X thinking there dollars therapeutics COVID-XX and pocket, with wondering, and hundreds While be this? small may and vaccines millions I this are we we following.

our plasma proven, broad seek development is of address preclinical to partners of hypothesis be range commercial trials. delivery mRNA vaccines is should and begin Also, immediate proven, we as possibility, agents. our there once Our hypothesis to expect Once viral technology will to validate goal we vector clinical our vaccines a in development studies is competitors. for using other COVID-XX DNA a infectious

and that didn't driving Now, staff dedicated individuals immunology, biology, molecular remiss has bring and outstanding point and our developed. role partners effort, advanced at this been with mention in researches, if the scientists I knowledge this of I'd who be our and of recently vaccine reinforced group

prototypes and to about comprised capability. saying produce advantaged of cautiously comments in build continue Board of vaccine researchers our Advisory and by on and highly continue vector field. chain have platform Vaccine optimistic conclude development be construction, research capacity a in we highly and analytical relationships assembled to the We've high We proof-of-concept excited PLACCINE I volumes methods, of regarded improved supply with potential. work my that to quantities its the our for partners

few sheet. a balance our Now, comments just on

completed We of $X operating sale available of with the improved also continue with our of most early to the cash of net to along take year. raise recent this million New capital this us our position various earlier We $XX.X of year. Jersey million losses sources April advantage State

flow about higher venture our runway debt which that quarter. bottom will stock Bank, million allowed now us $X strengthened we and to interest details the is of all smartly common of sheet, Valley balance that balance which We cash Jeff sell with year We the the an year approval our to next million us, in this few over our with by Silicon also sold way, new years. NOLS additional facility in improved an this $X.X available a be million that $XX can extends provide with cash investor-friendly later strengthened repay of through All a non-dilutive to sources just have transactions But capital, $X.X sheet, more further additional loan that NOLS. million financing. last is support received line XXXX.

earlier, of Our mentioned more cash important reach milestones, the to X PLACCINE study including development proof-of-concept from With to Church, go PFS call position, position. as I'll a I will OVATION Jeff? number our allow will that, financial initiative. turn over strong into reports the and about very our us detail Jeff who from

Jeffrey Church

Details XXXX open XX-Q, accrued Celsion's Michael. in were million of the quarter restricted we third and our you. and morning in of the XXXX in with which the issued market cash, we receivable. ended release cash this securities, filed $XX.X quarter, interest investment Form Thank results ed. press Celsion and third financial included before today

operating without any net past losses, the our to raised Jersey nearly million we is years, years operating of stockholders, equivalent New our to and of from have the which X sale expenses. $XX State nearly Over X dilution

resources per a which New NOLs Jersey last XXXX. Jersey approved by million year, XXXX $X.X future expected believe NOLs unused operations million. the available our Coupled Economic through of end we this of the for sale Jersey given about $X.X and is have to our week spending sale to plans, further New between sufficient of was net capital have Authority, XXXX. Company New the which current We with unused Development sales $X fund of we million

important to in are liquidity several support an respect to value-creating us through with milestones. excellent We position

results. review Let turn quarter to year-to-date XXXX and now our our third me financial of

loss were XXXX, a with loss compares XXth, or expenses September of $X.X quarter from XX $X.X third expenses September third $X.XX share. share, of This a ended the quarter this of Celsion the quarter which operating or for Operating $X.XX per for XXth, per is up $XXX,XXX reported the the million, quarter in $X.X year, about For of XXXX. $X.X net % million, million ended or million of net XXXX.

$XX.X in largely manufacturing XXXX. increase by fees, third million as higher for program, portion General discontinued decreased X as Clinical million OPTIMA $X.X expenses break a Research to premiums provided is year-to-date higher attributable XXXX. $XXX,XXX the OVATION trial of by of and $XXX,XXX the $XXX,XXX supplies basis, an professional same compared increase development me associated administrative largely On for of $X.X of Other was for third costs an fees, quarter by in study. DNA the development GEN-X the non-cash our in utilization Phase $XX.X prior $X.XX to was costs Phase average the sale XXX-patient development driven from this first quarter, for net cash is and Company's the used year. Jersey are of call XXXX, $XX.X Mike. for vaccine the of NOLs our of to to development Valley due offerings Let million first X this XXXX. third to from million and million, for will as Research with to the these the Cash million clinical and proceeds and derived during development related expense from from X primarily April, costs to in increase X costs with compared third to operating of per officers million quarter the May. the quarter in $X.X of line now XXXX the study $XXX,XXX lower the $X.X discontinuation to director with in $X.X insurance $X.X with manufacturing prior year XXXX and with million expenses study, of the well the activities OPTIMA $XXX,XXX, PLACCINE $XX were decreased stock Cash million quarter GEN-X down quarter. for compares for for quarter an in II period by of for Bank legal line This a quarter support last which our costs the this back million year, in million January $XXX,XXX. in facility as loan item. of and the $XX OVATION of financing compensation to technology in million the turn well the June, activities million New equity I months Silicon of offset in platform the related and about of projections prior-year or increased regulatory clinical approximately $X quarter. programs were

Michael Tardugno

to you, And make a then comment. Jeff. Thank quick want just I

us Our amount quite most industry insurance an costs increase. NOL us, including many industry certainly continued us, our like claims. the -- for seeing meritless high, costs is part enormous the are year to of to litigation, and The this companies for

shareholders to be medicines want to controlled I a our staff, that the our medical call driven commitment shareholders. open know are that legislators meritless meritless new recent drive focused we delivering to to through outrageous, our for we're that, shareholders. our we I daily talented to business against Operator? say community. them do needs the work We our be use to that ready that by to Supported against to encourage With our some With legislative please, clinicians, something would action. patients think technical you results, bring let questions. defend and the research and by our value to our and I this us, objectives to to of of financial scientists, addressed for to capital that claims is in and is create overview Would action needs investor contact you that our litigation you that know through of to this and just legislative as want remain

Operator

everyone Kumar moment signal first to comes to And allow questions. our [Operator Brookline Capital the opportunity pause with We'll for from for Raja a Instructions] question just Markets.

Kumar Raja

well Hi. congratulations the taking all Ovation Thanks Looks trial. terms for on the like progress. my doing questions the and are of enrollment you for in

back to recruitment? this to how end of terms What terms was you And you centers? are there Is are is COVID-XX? of In that that will seeing trial do the in you range? XXX XXX, it up seeing clinical of the think patient terms in in from different sites, different it you there where the before and levels what

Michael Tardugno

second you I II if So, like would first, study. is the don't -- question a mind. can Phase to This answer

months the here on to a do to XXX frankly more is to plan this data with XXX have study. goal the We're to designed and with the be have be? is data sufficient the it of we'll to an recently some COVID-XX, enrolling the enrollment, Phase that investigational reluctance ask patients. my power events, we pivotal have we max product, III. variant, variant is use variant, the the With this past to sufficient this to patient -- confidence to with patients. Our XX experience height original statistical data I I'm saw looking to was III patients XX up our to -- also. the of for regards But we more to ups for design have Where study. some The north -- expect the comment to whether challenge When [Indiscernible] be a study. Phase patients. head, in am of trial comment, this downs its we summer able we on to when trial. our The at hopeful power event-driven raised Nick or saw going -- the we've join the More is seen European wild-type Delta

guess just, of -- on a that's point think any comments pick up we're seeing my have you I that? Nick, I and view. from now I

Nicholas Borys

Mike. you, Thank

recruitment through in also, to as patient in and of As are screening it's cancer in problems for basically all with ovarian know, you hesitant an just probably is one isn't picked has cancer, you go good that the up can had there And pandemic ovarian symptoms. a really cancer guess, just process, patients ambiguous on screening. impact studies the sometimes

uptick saw to in More we enrollment now staffing So, problems we our at I Michael people the % we physicians timelines from patients. Then summer said, hospitals actively, we've pretty getting in were centers, as compared wave in a that the feeling continue checkups. for our going rate when are recently, good fall, an hit Michael their our are back enrolling very during we're good meet seen decrease. well and We're reports the safe second say and of still before. think to mentioned to And sites good a that enroll to pretty as XX the our And to getting fact overall. but optimistic I so participation. our have there's patients

Kumar Raja

the move vaccine, terms Okay. that you to steps for are DNA of next external the And what funding And are in there? looking forward?

Michael Tardugno

sufficient capital our proof-of-concept work. to have support We

applied or funding. through to the agencies, and we on Dr. rest but that do, regards grants have us to validation be applied have sufficient line Anwer to more, please? for think various we from what Got is whether is take not But capital With a line. question, our that's government we it's predict We of left think apply we'll you the pick want can't to government we to up is, is Obviously, appreciate. bottom successful. for the of work, proof-of-concept. we'll for Do to important if important

Khursheed Anwer

Thank you, Michael. Sure.

there's virus. SARS modeling objectives DNA-based a for X X for proof-of-concept benchmark plasmid, competitive that there to purpose. a are can products antigen commercial out of We've a demonstrate strains COVID you Our different been express because from single as

Our demonstrate of to -X a vaccine versus strains X a is a SARS demonstrate goal antigen asset the and detailed designed CoV a quarters for from responses strain vector and X of vector, single - that's that against effective EIGG, against strains generate antibodies, couple neutralizing can you single only. neutralization, single for in is next

from So opposed mRNA. demonstrate period to key DNA had DNA long earlier, stability to advantage muscle, experimentation, so the than for that's said better stability mRNA, expresses skeletal through Michael as the of thing. had inherently we have time as that

response our hypothesis from Our demonstrate you'll as to of that to mRNA. be immune able vectors durability

of of are have POC. of us demonstrating in You terms key the some objectives ahead that

Correct. activity be me the vector, current now, recent like accurate sir. to be coated. construct jump that Reasonable say for its just it's to is which our ways and would to antigens the in say, we're Yes, to ability that to Is produce looking Let of that say. it reasonable optimize for the And showing to factors. Khursheed, most able say?

Kumar Raja

of other there? are terms immunotherapy efforts in indication, for and And GEN-X oncology being update that front Okay. we what can done when an using in get

Michael Tardugno

I cancer think do we Phase show we positive intraperitoneal in that study to II is we're a optimistic so, some target any and fully us. results, once for cavity expect this that

decided the can We to pancreatic be which, haven't you that but colorectal cancers broaden on target. cancers. on And cancers that could But of include to please? from would more immediate any them range Khursheed, expand an liver maybe

Khursheed Anwer

now, product, we're delivery peritoneal Yes, after line, sure. make the cancer cancers same are cancers, immune Obviously, IL-XX, for local peritoneal also result and as % right this the with our And the next by cavity. XX these product so of depth, that is cancer you in would of cancer between changes GI cancer these GEN-X, ovarian XX different The pancreatic can really there is we're are peritoneal and going cancer, know, That said, of you ovarian intraperitoneal include be into gastric you metastasize colon favorable this Michael same the immunogenic. cancer, the that. the as disease liver developing, cancer Along because moving control about are also principle, and XX goal. and to environment. metastasized over % cavity patients % at least some to other the GI somewhere gamma

have activity against GI, GYN animal demonstrated We that in of GEN-X these models cancer.

cancer control with very approve to response disease ovarian demonstrated parallel go earlier. to local could should we be of be mentioned these would cancers, we one almost you think other ovarian we cancer, like that once that that then would after for said, I with just GI As cancer likely Michael of cancer, immune

Kumar Raja

look I taking to updates. questions. my Thanks forward so much for the

Michael Tardugno

Thank you.

Operator

comes Research. question Zacks Cap David next from with Bautz Small our And

David Bautz

everybody. morning, Good

question. So, question study. It's a the for technical is my first OVATION

is a when is opinion So, patient based or have that surgeon's the quantified? is on no to residual said disease, that somehow

Michael Tardugno

to it for on there's if is very residual the X left based any see review for any we're disease cavity looking of the left. to on what quantified Those of response surgeon's from the question. if at X findings and the final XX that -- CT pathological it's report. Yes, our in Thanks X, on that, pathology in play And seeing Number that typically there's disease levels. the evaluation sent And, overall where in X much the tissue as yeah, of that are also you removed then into is from and surgeon biggest role. that top probably in studies disease, % far, XX time. And at very PI is the our the know, in completely consistently, the studies time. large % meetings. of our response topic historically, found in feels most so RX we this discussion around they And of our

David Bautz

when you And as will study, Great. that. Thanks from it the it do sometime or additional as for to be it far be do releasing quarterly update call next at Will expect Okay. data the between that? that?

Michael Tardugno

that. between next within the enough to investigators. collect to results to to able be the by provide are weeks. be investigator-reported few supported to hopeful There probably in update information an enough able information collect Sometime We're

David Bautz

Okay.

understanding I the on lastly like COVID versus that that towards up correctly a And good. in Sounds you're vaccine, or air? is developing the leaning vaccine. still it Am more multi-strain sounds the multi-antigen vaccine

Michael Tardugno

a bit, correct, talk want please. that to you about it little have Christian You

Khursheed Anwer

objective Yes. David, a immune remember to X as our an antigens the and overall you vaccine is to modifier against with correctly, improve antivirus develop global quality.

we modification, the actually been change this have months, emerging is things virus equally for is pandemic However, as X last trend, important. that have SARS-CoV-X all learned and changing, this X, also

a in population have an may You stream. and a then dominant strain emerging

the developing, would So, seeing that you more stage. the of for strain X emerging an technology we quickly prudent the this stage strains, at and where to virus be that need is the this can hour conditions at the the develop prevalent be target it might the way feel

shown antigen Now, we multiple have vector for that shown a so least from the express X however, you same plus, gene have genes multi-systronic with the from were of of construction successfully. mentioned, also genes, And the approach -- single we we SARS-CoV-X trial at IL-XX, for sub-unit demonstrated spike a multi-systronic you of have multiple where that X expression antigen the can indeed plasmid antigen. M plasmid had XX, genes construction and

could that it. goal, so modifier So, X in you difficult to that pathogens. the shown which handle X you of strains that also, are immune build the activity this We co-express up the have effective be, antigens, really difficult to those could no same we with handle. on eventual could challenges RSV, there demonstrate do at some are thing. antigens. HIV, if genes vaccine of same believe that the certainly against an hour. it's feed X there's viruses address X SARS-CoV-X can stage. have different We if plasmid, we you And have IL-XX certain can

and a immune now modifiers, we've antigens sense incremental right that's an needed, To it's with and into built technology our down So, approach. the what's X road, going so. more

Michael Tardugno

more not points is this than more single be one which by disease. a of there minor more urgent. collaborator able we think system DNA than a change the one think the to is as in for can And antigens the capability variant compromised demonstrate just plasmid hypothesis to that out Anwer is one maybe all direction, an modifier at attractive -- and our of along immune -- Dr. with I protein produce -- more or

existing with may And medical different issue. so, this construct I really currently a the just of is we rapidly to the this prevailing is be than evaluated being end in ability could mean, beauty those that And ultimately the adapt that that vector the most up technology; proof-of-concept. The variance the for are construct.

David Bautz

antigens you're like X to -- strains that sounds limited can or you proteins just from different it So, you are express?

Michael Tardugno

No.

was proteins X that X proteins; we've and with X comments as proof think that I pretty clear as of Khursheed sub-unit for antigens, many in the shown IL-XX. concept 's

David Bautz

you appreciate taking I Okay. the All questions. great. right,

Michael Tardugno

Thank you. Thank you asking. for

Operator

Instructions]. [Operator

next Celsion. come Worth from will Our question with Mike

Michael Tardugno

Hello, Mike.

Mike Worth

How you as goes. doing, you if wondering guys sir. update was any had from the fast-track FDA are or guys I designation the as you far

Michael Tardugno

the an was Fast-track was we over granted submitted OVATION application That X designation summer. that based on study. granted the

for exclusive While granted the that in relatively in has be to from orphan medical designation. with need the required fast-track has that among provide evidence track, for that potential, for FDA it's GEN-X, in things, that medical early of would granted therapy other of with ovarian along U.S. our a of deal provide has been generally to a some I recognizes case basis -- therapeutics grant many on the and with, disease some unmet ovarian approach or that The suggests Along standpoint as doing XX it's work Europe some the urgency cancer, with this of evidence X in serious a -- potential of has these patients. study data unaddressed granted and us high for the successful course, cancer say designation importance that Europe has regulatory with this program. not treatment a FDA needs, an provides of potential, great that A taking finding years cure. we're in Orphan a years. we an which to the some we're is -- FDA has a improvement and the that U.S. Fast-tack, us very the been market alone. and but

Mike Worth

Right.

So, -- data good end more the the currently phase is come it's [Indiscernible] of to is will the shows it's go questions. that that the each way or a That's there if by the so Phase X it promising with of end at showing? updates

Michael Tardugno

you. get I

the trials, including ongoing interface with a could effectiveness. to agency study think of I or as evaluate come of the NDA, where endpoints which Fast for value, opportunity, ongoing. on certainly review they provides up development, discussion approvals the clinical design, that are I surrogate in allows with the quicker amount. Those clinic fast-track considering up the to of substantial fast-track application various give ends the the to by course, that's time reduce be with Track the stage, a review able means consider of at amount priority approaches our demonstrate and during the to in kind said, the BLA course of an to a drug's -- on a the us your to design case as the the the for questions we're the faster Company time FDA Along at Ultimately, opportunity, So, reduces the designation efficacy. of the this

hope answers I question. So, your that

Mike Worth

you, Thank sir.

Michael Tardugno

you. Thank

Operator

to concludes our the Tardugno will - closing session. And A call remarks. for back question-and-answer turn that over Michael I

Michael Tardugno

opportunity those available. and conference studies of excitement we look of more our asked questions, who we the them the which is real all in which questions, deal gives some perhaps all about We work great your vaccine expand our agents trust Francisco joining I for for potential we're this It keeping person. and the given our on have hope, to a get appreciate as in conveyed development morning, that related seeing GEN-X there forward and of progress. call Thanks, immunotherapy for have, platform, thank do questions, informed to for San to and to you number you, you you morning. I'm really doing. PLACCINE questions this may for an our that on you progress, no vaccine your of or we've encourage we'll concerns the of And have to sure again, infectious we our But continue I've more time want

during in be can held meeting. it schedule will attending our week contacting JP understand make N.J. a if to by arrangements please of with us, we second to through speak now, we wish are firm IR you As And Healthcare the Conference and January. Morgan -person

conference we'll call this that, much. thank and very with all you conclude So,

Operator

This today's you. call. Thank concludes

You may now disconnect.

Imunon (IMNN) 15 Nov 212021 Q3 Earnings call transcript